Abbott Laboratories $ABT Shares Acquired by Gateway Wealth Partners LLC

Gateway Wealth Partners LLC increased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 994.2% during the first quarter, HoldingsChannel reports. The institutional investor owned 23,995 shares of the healthcare product maker’s stock after acquiring an additional 21,802 shares during the period. Gateway Wealth Partners LLC’s holdings in Abbott Laboratories were worth $2,463,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. MidAtlantic Capital Management Inc. purchased a new position in Abbott Laboratories during the fourth quarter valued at $25,000. Cornerstone Financial Management LLC purchased a new stake in shares of Abbott Laboratories during the fourth quarter worth about $25,000. Purpose Unlimited Inc. acquired a new position in shares of Abbott Laboratories during the 4th quarter worth about $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in Abbott Laboratories in the 4th quarter valued at about $26,000. Finally, Abound Financial LLC purchased a new position in Abbott Laboratories in the 4th quarter valued at about $26,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on the company. UBS Group cut their price objective on Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating for the company in a research note on Monday, April 20th. Benchmark lowered their price target on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Bank of America dropped their price target on Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Citigroup increased their price objective on Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research note on Friday, July 17th. Finally, Barclays lowered their target price on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a research note on Monday, April 20th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $118.61.

Abbott Laboratories Stock Up 1.5%

NYSE ABT opened at $104.61 on Tuesday. The business’s fifty day simple moving average is $91.95 and its 200-day simple moving average is $100.99. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The firm has a market cap of $182.20 billion, a PE ratio of 33.85, a P/E/G ratio of 2.00 and a beta of 0.61. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.51 billion during the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. Abbott Laboratories’s revenue was up 13.0% compared to the same quarter last year. During the same period last year, the business earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.